Potential role of acid ceramidase in conversion of cytostatic to cytotoxic end-point in pancreatic cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 3, 2013, Pages 635-645

  Morad, Samy A F ^a,c   Messner, Maria C ^a   Levin, Jonathan C ^a   Abdelmageed, Noha ^a   Park, Hyejung ^b   Merrill Jr , Alfred H ^b   Cabot, Myles C ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c South Valley University   (Egypt)

Author keywords

Acid ceramidase; Ceramide; Pancreatic cancer; PSC 833; Sphingolipid

Indexed keywords

ACID CERAMIDASE; ACRIDINE ORANGE; ANTINEOPLASTIC AGENT; CERAMIDE; DM 102; GLUCOSYLCERAMIDE; HYDROGEN PALMITATE C 3; N (1 HYDROXYOCTADEC 3 EN 2 YL)PIVALOYLAMINE; RADIOPHARMACEUTICAL AGENT; RETINOBLASTOMA PROTEIN; SPHINGOMYELIN; THERMOZYMOCIDIN; UNCLASSIFIED DRUG; VALSPODAR; (2R,3Z) N (1 HYDROXYOCTADEC 3 EN 2 YL)PIVALAMIDE; (2R,3Z)-N-(1-HYDROXYOCTADEC-3-EN-2-YL)PIVALAMIDE; AMIDE; CYCLOSPORIN DERIVATIVE; DNA; MULTIDRUG RESISTANCE PROTEIN; SPHINGOLIPID; UNSATURATED FATTY ACID;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DNA FRAGMENTATION; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; ENZYME INHIBITION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LIPID METABOLISM; MASS SPECTROMETRY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STAINING; ANIMAL; BIOASSAY; BIOSYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; THIN LAYER CHROMATOGRAPHY; TUMOR CELL LINE; WESTERN BLOTTING;

ACID CERAMIDASE; ACRIDINE ORANGE; AMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMATOGRAPHY, THIN LAYER; CYCLOSPORINS; DNA FRAGMENTATION; DNA, NEOPLASM; ENDPOINT DETERMINATION; FATTY ACIDS, UNSATURATED; FLOW CYTOMETRY; HUMANS; MASS SPECTROMETRY; P-GLYCOPROTEIN; PANCREATIC NEOPLASMS; SPHINGOLIPIDS;

MLCS; MLOWN;

EID: 84875855187     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2050-4     Document Type: Article

References (45)

1. Abe A, Radin NS, Shayman JA, Wotring LL, Zipkin RE, Sivakumar R, Ruggieri JM, Carson KG, Ganem B (1995) Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J Lipid Res 36:611-621
2. Bedia C, Canals D, Matabosch X, Harrak Y, Casas J, Llebaria A, Delgado A, Fabrias G (2008) Cytotoxicity and acid ceramidase inhibitory activity of 2-substituted aminoethanol amides. Chem Phys Lipids 156:33-40
3. Bedia C, Casas J, Garcia V, Levade T, Fabrias G (2007) Synthesis of a novel ceramide analogue and its use in a high-throughput fluorogenic assay for ceramidases. ChemBioChem 8:642-648 (Pubitemid 47194856)
4. Bedia C, Levade T, Codogno P (2011) Regulation of autophagy by sphingolipids. Anticancer Agents Med Chem 11:844-853
5. Bektas M, Jolly PS, Muller C, Eberle J, Spiegel S, Geilen CC (2005) Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 24:178-187 (Pubitemid 40143877)
6. Bielawska A, Greenberg MS, Perry D, Jayadev S, Shayman JA, McKay C, Hannun YA (1996) (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. J Biol Chem 271:12646-12654 (Pubitemid 26333228)
7. Bleicher RJ, Cabot MC (2002) Glucosylceramide synthase and apoptosis. Biochim Biophys Acta 1585:172-178 (Pubitemid 36092082)
8. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911-917
9. Cabot MC, Han TY, Giuliano AE (1998) The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation. FEBS Lett 431:185-188 (Pubitemid 28334213)
10. Canals D, Perry DM, Jenkins RW, Hannun YA (2011) Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. Br J Pharmacol 163:694-712
11. Eckstein LA, Van Quill KR, Bui SK, Uusitalo MS, O'Brien JM (2005) Cyclosporin a inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells. Invest Ophthalmol Vis Sci 46:782-790 (Pubitemid 41321012)
12. Fabrias G, Bedia C, Casas J, Abad JL, Delgado A (2011) Ceramidases in hematological malignancies: senseless or neglected target? Anticancer Agents Med Chem 11:830-843
13. Flowers M, Fabrias G, Delgado A, Casas J, Abad JL, Cabot MC (2012) C6-Ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth. Breast Cancer Res Treat 133:447-458
14. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315-2319
15. Gatt S (1963) Enzymic hydrolysis and synthesis of ceramides. J Biol Chem 238:3131-3133
16. Gouaze-Andersson V, Cabot MC (2011) Sphingolipid metabolism and drug resistance in hematological malignancies. Anticancer Agents Med Chem 11:891-903
17. Gouaze-Andersson V, Flowers M, Karimi R, Fabrias G, Delgado A, Casas J, Cabot MC (2011) Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide. Prostate 71:1064-1073
18. Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, Delisle MB, Cuvillier O, Susini C, Bousquet C (2009) Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther 8:809-820
19. Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C (2010) Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 11:358-365
20. Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, Keyomarsi K (2008) Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 68:7966-7974
21. Lehne G, Sorensen DR, Tjonnfjord GE, Beiske C, Hagve TA, Rugstad HE, Clausen OP (2002) The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice. Leukemia 16:2388-2394 (Pubitemid 36054372)
22. Leonard GD, Polgar O, Bates SE (2002) ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 3:1652-1659 (Pubitemid 36266743)
23. Liu X, Cheng JC, Turner LS, Elojeimy S, Beckham TH, Bielawska A, Keane TE, Hannun YA, Norris JS (2009) Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets 13:1449-1458
24. Liu X, Elojeimy S, Turner LS, Mahdy AE, Zeidan YH, Bielawska A, Bielawski J, Dong JY, El-Zawahry AM, Guo GW, Hannun YA, Holman DH, Rubinchik S, Szulc Z, Keane TE, Tavassoli M, Norris JS (2008) Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci 13:2293-2298 (Pubitemid 351589254)
25. Lu Z, Kleeff J, Shrikhande S, Zimmermann T, Korc M, Friess H, Buchler MW (2000) Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas 21:240-247
26. Maeda I, Takano T, Matsuzuka F, Maruyama T, Higashiyama T, Liu G, Kuma K, Amino N (1999) Rapid screening of specific changes in mRNA in thyroid carcinomas by sequence specific-differential display: decreased expression of acid ceramidase mRNA in malignant and benign thyroid tumors. Int J Cancer 81:700-704 (Pubitemid 29214376)
27. Mahdy AE, Cheng JC, Li J, Elojeimy S, Meacham WD, Turner LS, Bai A, Gault CR, McPherson AS, Garcia N, Beckham TH, Saad A, Bielawska A, Bielawski J, Hannun YA, Keane TE, Taha MI, Hammouda HM, Norris JS, Liu X (2009) Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther 17:430-438
28. Merrill AH Jr, Sullards MC, Allegood JC, Kelly S, Wang E (2005) Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 36:207-224 (Pubitemid 40726151)
29. Messner MC, Cabot MC (2011) Cytotoxic responses to N-(4-hydroxyphenyl) retinamide in human pancreatic cancer cells. Cancer Chemother Pharmacol 68:477-487
30. Mizushima N, Yoshimori T (2007) How to interpret LC3 immunoblotting. Autophagy 3:542-545 (Pubitemid 350060049)
31. Modrak DE, Leon E, Goldenberg DM, Gold DV (2009) Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines. Mol Cancer Res 7:890-896
32. Morales A, Paris R, Villanueva A, Llacuna L, Garcia-Ruiz C, Fernandez-Checa JC (2007) Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo. Oncogene 26:905-916
33. Musumarra G, Barresi V, Condorelli DF, Scire S (2003) A bioinformatic approach to the identification of candidate genes for the development of new cancer diagnostics. Biol Chem 384:321-327 (Pubitemid 36348334)
34. Park JH, Schuchman EH (2006) Acid ceramidase and human disease. Biochim Biophys Acta 1758:2133-2138 (Pubitemid 44879370)
35. Ryland LK, Fox TE, Liu X, Loughran TP, Kester M (2011) Dysregulation of sphingolipid metabolism in cancer. Cancer Biol Ther 11:138-149
36. Saddoughi SA, Song P, Ogretmen B (2008) Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 49:413-440
37. Samsel L, Zaidel G, Drumgoole HM, Jelovac D, Drachenberg C, Rhee JG, Brodie AM, Bielawska A, Smyth MJ (2004) The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 58:382-393 (Pubitemid 38295032)
38. Shaner RL, Allegood JC, Park H, Wang E, Kelly S, Haynes CA, Sullards MC, Merrill AH Jr (2009) Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers. J Lipid Res 50:1692-1707
39. Siddique MM, Bikman BT, Wang L, Ying L, Reinhardt E, Shui G, Wenk MR, Summers SA (2012) Ablation of dihydroceramide desaturase confers resistance to etoposide-induced apoptosis in vitro. PLoS ONE 7:e44042
40. Strub GM, Maceyka M, Hait NC, Milstien S, Spiegel S (2010) Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol 688:141-155
41. Sullards MC, Allegood JC, Kelly S, Wang E, Haynes CA, Park H, Chen Y, Merrill AH Jr (2007) Structure-specific, quantitative methods for analysis of sphingolipids by liquid chromatography-tandem mass spectrometry: "inside-out" sphingolipidomics. Methods Enzymol 432:83-115
42. Wang H, Maurer BJ, Liu YY, Wang E, Allegood JC, Kelly S, Symolon H, Liu Y, Merrill AH Jr, Gouaze-Andersson V, Yu JY, Giuliano AE, Cabot MC (2008) N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. Mol Cancer Ther 7:2967-2976
43. Yang K, Wu J, Li X (2008) Recent advances in the research of P-glycoprotein inhibitors. Biosci Trends 2:137-146
44. Zeidan YH, Jenkins RW, Korman JB, Liu X, Obeid LM, Norris JS, Hannun YA (2008) Molecular targeting of acid ceramidase: implications to cancer therapy. Curr Drug Targets 9:653-661
45. Zheng W, Kollmeyer J, Symolon H, Momin A, Munter E, Wang E, Kelly S, Allegood JC, Liu Y, Peng Q, Ramaraju H, Sullards MC, Cabot M, Merrill AH Jr (2006) Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim Biophys Acta 1758:1864-1884 (Pubitemid 44879367)